{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:36:33Z","timestamp":1792028193440,"version":"4.4.0"},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,5,20]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Patients with centrally located early-stage non\u2013small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology\/RTOG 0813 was a phase I\/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC. <\/jats:p><\/jats:sec><jats:sec><jats:title>MATERIALS AND METHODS<\/jats:title><jats:p> Medically inoperable patients with biopsy-proven, positron emission tomography\u2013staged T1 to 2 (\u2264 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy\/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> One hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume\/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy\/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy\/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> The MTD for this study was 12.0 Gy\/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.18.00622","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T19:59:51Z","timestamp":1554321591000},"page":"1316-1325","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":507,"title":["Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non\u2013Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial"],"prefix":"10.1200","volume":"37","author":[{"given":"Andrea","family":"Bezjak","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Paulus","sequence":"additional","affiliation":[{"name":"NRG Oncology, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie E.","family":"Gaspar","sequence":"additional","affiliation":[{"name":"University of Colorado Denver, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Timmerman","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Straube","sequence":"additional","affiliation":[{"name":"Washington University in St Louis, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pocono Medical Center, East Stroudsburg, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda I.","family":"Garces","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Pu","sequence":"additional","affiliation":[{"name":"Sutter General Hospital, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Videtic","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"McGarry","sequence":"additional","affiliation":[{"name":"University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Pantarotto","sequence":"additional","affiliation":[{"name":"Ottawa Hospital and Cancer Center, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Urbanic","sequence":"additional","affiliation":[{"name":"University of California, San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Sun","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Daly","sequence":"additional","affiliation":[{"name":"University of California, Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga S.","family":"Grills","sequence":"additional","affiliation":[{"name":"William Beaumont Hospital, Royal Oak, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sperduto","sequence":"additional","affiliation":[{"name":"Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Normolle","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Washington University in St Louis, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak","family":"Choy","sequence":"additional","affiliation":[{"name":"The University of Texas Southwestern, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3747\/co.24.3358"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2017.04.014"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.261"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.0731"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.5937"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.11.042"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3844"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2015.09.012"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.04.014"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.369"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.03.008"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000484"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.08.345"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.01.022"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.08.008"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.09.028"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160113"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.18.00622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:03:17Z","timestamp":1653811397000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.18.00622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":17,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,5,20]]}},"alternative-id":["10.1200\/JCO.18.00622"],"URL":"https:\/\/doi.org\/10.1200\/jco.18.00622","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"2019-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}